关注
Haertter, S.
Haertter, S.
在 boehringer-ingelheim.com 的电子邮件经过验证
标题
引用次数
引用次数
年份
Dabigatran etexilate–a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity
J Van Ryn, J Stangier, S Haertter, KH Liesenfeld, W Wienen, M Feuring, ...
Thrombosis and haemostasis 103 (06), 1116-1127, 2010
18712010
Pharmacokinetics of selective serotonin reuptake inhibitors
C Hiemke, S Härtter
Pharmacology & therapeutics 85 (1), 11-28, 2000
10332000
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY …
PA Reilly, T Lehr, S Haertter, SJ Connolly, S Yusuf, JW Eikelboom, ...
Journal of the American College of Cardiology 63 (4), 321-328, 2014
10052014
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial
KH Liesenfeld, T Lehr, C Dansirikul, PA Reilly, SJ Connolly, ...
Journal of Thrombosis and Haemostasis 9 (11), 2168-2175, 2011
3892011
A review of the receptor-binding and pharmacokinetic properties of dopamine agonists
T Kvernmo, S Härtter, E Burger
Clinical therapeutics 28 (8), 1065-1078, 2006
3402006
Genetic determinants of dabigatran plasma levels and their relation to bleeding
G Paré, N Eriksson, T Lehr, S Connolly, J Eikelboom, MD Ezekowitz, ...
Circulation 127 (13), 1404-1412, 2013
3352013
CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine
MEE Shams, B Arneth, C Hiemke, A Dragicevic, MJ Müller, R Kaiser, ...
Journal of clinical pharmacy and therapeutics 31 (5), 493-502, 2006
3042006
Effective elimination of dabigatran by haemodialysis
D Khadzhynov, F Wagner, S Formella, E Wiegert, V Moschetti, T Slowinski, ...
Thrombosis and haemostasis 109 (04), 596-605, 2013
2572013
A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral …
F Van de Werf, M Brueckmann, SJ Connolly, J Friedman, CB Granger, ...
American heart journal 163 (6), 931-937. e1, 2012
2432012
Elevated levels of clozapine in serum after addition of fluvoxamine
C Hiemke, H Weigmann, S HÄRTTER, N Dahmen, H Wetzel, H MÜLLER
Journal of clinical psychopharmacology 14 (4), 279-280, 1994
2291994
Oral bioavailability of dabigatran etexilate (Pradaxa®) after co‐medication with verapamil in healthy subjects
S Härtter, R Sennewald, G Nehmiz, P Reilly
British journal of clinical pharmacology 75 (4), 1053-1062, 2013
2052013
Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds—implications for pharmacokinetics of selected substrates
A Abou El Ela, S Härtter, U Schmitt, C Hiemke, H Spahn-Langguth, ...
Journal of Pharmacy and Pharmacology 56 (8), 967-975, 2004
1852004
Decrease in the oral bioavailability of dabigatran etexilate after co‐medication with rifampicin
S Härtter, M Koenen‐Bergmann, A Sharma, G Nehmiz, U Lemke, ...
British journal of clinical pharmacology 74 (3), 490-500, 2012
1592012
Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin
S Härtter, X Wang, H Weigmann, T Friedberg, M Arand, F Oesch, ...
Journal of clinical psychopharmacology 21 (2), 167-174, 2001
1352001
Automated analysis of quetiapine and other antipsychotic drugs in human blood by high performance-liquid chromatography with column-switching and spectrophotometric detection
J Sachse, J Köller, S Härtter, C Hiemke
Journal of Chromatography B 830 (2), 342-348, 2006
1312006
Increased bioavailability of oral melatonin after fluvoxamine coadministration
S Härtter, M Grözinger, H Weigmann, J Röschke, C Hiemke
Clinical Pharmacology & Therapeutics 67 (1), 1-6, 2000
1282000
Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data.
A Szegedi, H Wetzel, M Leal, S Härtter, C Hiemke
The Journal of clinical psychiatry 57 (6), 257-264, 1996
1261996
Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation
T Lehr, S Haertter, KH Liesenfeld, A Staab, A Clemens, PA Reilly, ...
The Journal of Clinical Pharmacology 52 (9), 1373-1378, 2012
1192012
The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia
G Gründer, C Landvogt, I Vernaleken, HG Buchholz, J Ondracek, ...
Neuropsychopharmacology 31 (5), 1027-1035, 2006
1192006
Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity
S Härtter, A Nordmark, DM Rose, L Bertilsson, G Tybring, K Laine
British journal of clinical pharmacology 56 (6), 679-682, 2003
1052003
系统目前无法执行此操作,请稍后再试。
文章 1–20